For instance, alpha-galactosidase-A (moss-aGal) has been used for Fabry disease (phase 1; Veen et al., 2020), HIV-neutralizing human mAb 2G12 (phase 1; Tremouillaux-Guiller et al., 2020), HA VLP influenza vaccine (phase 2; Pillet et al., 2019), anti-Ebola IgG cocktail (ZMApp) for the treatment of Ebola infection (phase 2/3; Davey et al., 2016) and glucocerebrosidase enzyme (ELELYSO) for Gaucher’s disease (Fox, 2012). Here, GLA is linked to Gaucher disease.